Bridgebio Pharma

BridgeBio lost money on operations at a -104.2% margin and still carries a roughly $13 billion market cap.

If you own BBIO, you own a drug pipeline story, not a normal operating business.

bbio

healthcare large cap updated feb 27, 2026
$75.25
market cap ~$13B · 52-week range $28–$85
xvary composite: 60 / 100 · average
our overall rating — combines growth, value, risk, and momentum
Start here if you're new
what it is
BridgeBio builds drugs for rare genetic diseases and hopes a few winners can pay for a very expensive search.
how it gets paid
Last year Bridgebio Pharma made $502M in revenue.
why it's growing
Revenue grew 126.3% last year. Latest-quarter revenue rose 188% vs. prior year, while annual revenue reached $502M, up 126.3%.
what just happened
The quarter said one thing loudly: revenue hit $348M, but EPS still landed at -$2.79, so scale has not fixed the income statement.
At a glance
B+ balance sheet — decent shape, but not bulletproof
80/100 earnings predictability — you can trust these numbers
-$3.44 fy2024 eps est
$222M fy2024 rev est
n/a operating margin
xvary composite: 60/100 — average
What they do
BridgeBio builds drugs for rare genetic diseases and hopes a few winners can pay for a very expensive search.
This is not a fortress. It is a shot portfolio. BridgeBio has created 19 INDs (investigational new drug applications → permission to start human testing → proof the pipeline is real) and already has 3 FDA approvals, which gives you more ways to win than a one-asset biotech. The quiet part: when most peers live or die by one trial, BridgeBio can survive one miss because it spread the bet across more than 40 disease states.
healthcare large-cap biotech rare-disease pipeline
How they make money
$502M annual revenue · their business grew +126.3% last year
total revenue
$502M
+126.3%
The products that matter
commercial drug
attruby
$108.1M quarterly sales
this is the product paying the bills today. it generated $108.1M in quarterly sales, and the stock is priced as if that number keeps climbing fast.
the core story
pipeline program
bbp-418
2027 launch plan watch
management is pointing investors toward an interim analysis and a 2027 launch plan. until data lands, this is promise more than proof.
pipeline upside
additional asset
infigratinib
important, but thin here
it matters because BBIO needs more than one winner. this snapshot does not give enough numbers to make it the center of the case.
secondary option
Key numbers
$280M
revenue gap
One published FY2024 estimate shows $222M, while BridgeBio's SEC filing shows $502M. Plain English: your starting sales base changes by $280M, so every valuation shortcut changes with it.
n/a
operating margin
Prior margin KPI failed sanity check — verify in filings. Operating margin → profit after running the business → so what: BridgeBio still loses more than it sells.
$2.7B
long-term debt
Debt is real even when biotech stories are dreamy. Against a roughly $13B market cap, this is not a tiny footnote.
19
IND filings
INDs → applications to start human trials → so what: BridgeBio has built a much wider pipeline than the average single-asset biotech.
Financial health
B+
strength
  • balance sheet grade B+ — solid but not elite
  • risk rank 2 — safer than 80% of stocks
  • price stability 5 / 100
  • long-term debt $2.7B (17% of capital)
B+ — functional but not a standout on the balance sheet.
Total return vs. market

Return history isn't available for BBIO right now.

same standard. no invented return math.

source: institutional data · return history unavailable
What just happened
missed estimates
The quarter said one thing loudly: revenue hit $348M, but EPS still landed at -$2.79, so scale has not fixed the income statement.
Latest-quarter revenue rose 188% vs. prior year, while annual revenue reached $502M, up 126.3%. The quiet part: sales are showing up faster than profits, which is normal for biotech launches but still expensive.
$348M
revenue
$2.79
eps
188%
revenue growth
the number that mattered
$348M matters most because it shows BridgeBio can now produce real top-line scale, even while earnings remain deeply negative.
source: company earnings report, 2026

Get this snapshot in your inbox

This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.

weekly updates earnings alerts plain english no spam
What could go wrong

The #1 risk is Attruby concentration colliding with the Pfizer tafamidis patent fight. One drug is driving the commercial story, and that same asset is exposed to both legal noise and competitive pressure.

∘
med
Attruby is carrying too much of the valuation
BBIO trades near $13B while the clearest operating proof point on the page is $108.1M in quarterly sales from one drug. If that ramp slows, the stock loses its cleanest justification.
BBIO trades near $13B while the clearest operating proof point on the page is $108.1M in quarterly sales from one drug. If that ramp slows, the stock loses its cleanest justification.
∘
med
Pipeline upside is still mostly pre-proof
BBP-418 matters because BBIO needs another leg to the story. Until the interim analysis lands, investors are underwriting a 2027 launch plan without having the full readout in hand.
BBP-418 matters because BBIO needs another leg to the story. Until the interim analysis lands, investors are underwriting a 2027 launch plan without having the full readout in hand.
∘
med
Debt makes execution matter more
$2.7B of long-term debt is manageable only if commercial traction keeps improving. In a biotech, balance sheet strength helps. Cash generation helps more.
$2.7B of long-term debt is manageable only if commercial traction keeps improving. In a biotech, balance sheet strength helps. Cash generation helps more.
If you own BBIO, you are betting that future drug wins outrun a current business that still loses money on every dollar of sales.
source: institutional data · regulatory filings · risk analysis
Pay attention to
legal risk
the Pfizer tafamidis case is not background noise
A judge ruled Pfizer can present its arguments. If the legal path gets worse, the market will have to revisit how durable Attruby really is.
calendar
BBP-418 interim analysis
This is the next real pipeline catalyst. The 2027 launch plan sounds good today. Data is what decides whether it deserves to survive.
metric
Attruby sales after the $108.1M quarter
One strong quarter gets attention. A string of them gets a premium multiple. This is the cleanest operating metric on the page.
trend
estimate revisions versus stock reality
HC Wainwright raised estimates. Watch whether estimate upgrades keep following the launch, or whether the stock has already priced in most of the good news.
Analyst rankings
earnings predictability
80 / 100
in human-speak, the company has been more consistent than you might expect for a biotech.
balance sheet grade
B+
Good enough to support the story. Not strong enough to make you forget the execution risk.
risk rank
2
Lower is better here. This score says safer than 80% of stocks on the provider's framework.
price stability
5 / 100
Translation: the fundamentals may be improving, but the stock can still throw furniture around the room.
source: institutional data
Institutional activity

institutional ownership data for BBIO is being compiled.

source: institutional data
source: institutional data
Price targets
3-5 year target range
n/a n/a
$75 current price
n/a target midpoint · n/a from current
target data not available

Want the deeper analysis?

The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.

see plans from $5/mo
The deep dive
BBIO
xvary deep dive
bbio
the full analysis is in the works.
what you'll get
dcf valuation model
bull / base / bear scenarios
competitive moat breakdown
quarterly earnings tracker
operating model projections
risk matrix with kill criteria
original price target + conviction
updated with every earnings
free · no spam · you'll be first to read it